Kurma Partners has announced the first closing of its Biofund IV at €140 million (US$154.5 million) and is pressing ahead to a final close of €250 million this time next year. The fund will make 16 to 20 investments, with half the money due to be invested in novel science that Kurma teases out of academic labs and the remainder in established VC-funded companies. The Paris-based firm is agnostic about which fields or disease areas it invests in and will prospect for breakthrough research anywhere in Europe.
Flagship Pioneering and Singapore’s Agency for Science, Technology and Research (A*STAR) are jointly committing up to SGD100 million (US$77.12 million) over the next five years to drive inter-party R&D collaboration and biotech creation in Singapore.
Taiwan’s Caliway Biopharmaceuticals Co. Ltd. raised NT$6.4 billion (US$206 million) in its IPO on the Taipei Stock Exchange, making it the largest IPO in Taiwan’s biotech industry history and valuing the company at nearly $3 billion following the listing.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aldeyra, Astrazeneca, Avidity, Stemcyte.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Eli Lilly, Eton, Gigagen, Ipsen, Kineta, Liquidia, Mabxience, Pharmosa, Teva, Tuhura.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abivax, Ennodc, Expert Systems, Irlab, Theriva, Trawsfynydd.
South San Francisco-based Septerna Inc. filed an S-1 with the U.S. SEC to conduct an IPO on Nasdaq about two years and eight months after launching operations with a $100 million series A led by Third Rock Ventures. The company is focused on G protein-coupled receptor oral small molecules derived from its Native Complex Platform, aimed at treating diseases within the endocrinology, immunology and inflammation, and metabolic diseases realms.
RSS
